(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.
The three biggest winners today are Tattooed Chef, Zai Lab, and BeiGene.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | Tattooed Chef (TTCF) | 0.31 | 6.44% | 2023-07-05 04:47:24 |
| 2 | Zai Lab (ZLAB) | 30.03 | 4.38% | 2023-07-05 04:37:19 |
| 3 | BeiGene (BGNE) | 188.50 | 4.23% | 2023-07-05 07:28:30 |
| 4 | Fidelity National Information Services (FIS) | 59.90 | 3.28% | 2023-07-05 07:33:28 |
| 5 | Castle Biosciences (CSTL) | 13.97 | 3.13% | 2023-07-05 07:28:52 |
| 6 | Fastenal Company (FAST) | 60.17 | 3.01% | 2023-07-05 07:24:19 |
| 7 | Sumitomo Mitsui (SMFG) | 8.90 | 3.01% | 2023-07-05 04:44:46 |
| 8 | Genuine Parts Company (GPC) | 173.03 | 3% | 2023-07-05 04:40:55 |
| 9 | Astrazeneca (AZN) | 67.08 | 2.8% | 2023-07-05 04:38:04 |
| 10 | Ebix (EBIX) | 26.99 | 2.78% | 2023-07-05 07:24:08 |
The three biggest losers today are West Pharmaceutical, Canopy Growth, and Upland Software.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | West Pharmaceutical (WST) | 343.01 | -9.34% | 2023-07-05 07:22:18 |
| 2 | Canopy Growth (CGC) | 0.56 | -4.41% | 2023-07-05 07:22:39 |
| 3 | Upland Software (UPLD) | 3.57 | -4.02% | 2023-07-05 07:27:49 |
| 4 | Riot Blockchain (RIOT) | 12.84 | -3.81% | 2023-07-05 07:29:59 |
| 5 | DISH Network (DISH) | 6.52 | -3.69% | 2023-07-05 07:23:54 |
| 6 | Marathon (MARA) | 14.77 | -3.59% | 2023-07-05 07:25:57 |
| 7 | Banco Santander (SAN) | 3.62 | -3.47% | 2023-07-05 04:44:29 |
| 8 | Aurora Cannabis (ACB) | 0.56 | -3.46% | 2023-07-05 04:47:08 |
| 9 | Prudential Public Limited Company (PUK) | 27.38 | -3.22% | 2023-07-05 04:44:02 |
| 10 | Wipro Limited (WIT) | 4.64 | -3.13% | 2023-07-05 04:46:14 |
Premarket Winners today
1. Tattooed Chef (TTCF) – Premarket: 6.44%
Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, wood fire crusted pizza, handheld burritos, and bars and quesadillas. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores, as well as online. Tattooed Chef, Inc. is headquartered in Paramount, California.
NASDAQ ended the session with Tattooed Chef falling 46.79% to $0.29 on Wednesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Tattooed Chef has a trailing twelve months EPS of $-1.7.
More news about Tattooed Chef.
2. Zai Lab (ZLAB) – Premarket: 4.38%
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.
NASDAQ ended the session with Zai Lab jumping 3.75% to $28.77 on Wednesday while NASDAQ jumped 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Zai Lab has a trailing twelve months EPS of $-4.2.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.51%.
More news about Zai Lab.
3. BeiGene (BGNE) – Premarket: 4.23%
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
NASDAQ ended the session with BeiGene jumping 1.43% to $180.85 on Wednesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, BeiGene has a trailing twelve months EPS of $-18.57.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.18%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BeiGene’s stock is considered to be oversold (<=20).
Moving Average
BeiGene’s value is way below its 50-day moving average of $226.75 and way under its 200-day moving average of $212.99.
Volatility
BeiGene’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.19%, a negative 1.09%, and a positive 2.03%.
BeiGene’s highest amplitude of average volatility was 0.77% (last week), 1.52% (last month), and 2.03% (last quarter).
Sales Growth
BeiGene’s sales growth is 51.1% for the present quarter and 48.9% for the next.
More news about BeiGene.
4. Fidelity National Information Services (FIS) – Premarket: 3.28%
Fidelity National Information Services, Inc. provides technology solutions for financial institutions and businesses worldwide. It operates through Banking Solutions, Merchant Solutions, and Capital Market Solutions segments. The Banking Solutions segment provides core processing and ancillary applications; mobile and online banking; fraud, risk management, and compliance; electronic funds transfer and network; card and retail payment; wealth and retirement; and item processing and output solutions. The Merchant Solutions segment offers small- to medium-sized businesses acquiring, enterprise acquiring, and ecommerce solutions. The Capital Market Solutions segment provides investment operations and data, lending, trading and processing, and treasury and risk solutions. The company was founded in 1968 and is headquartered in Jacksonville, Florida.
NYSE ended the session with Fidelity National Information Services rising 6.03% to $58.00 on Wednesday, after four sequential sessions in a row of gains. NYSE rose 0.27% to $15,918.50, after three consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Fidelity National Information Services has a trailing twelve months EPS of $-27.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.91%.
More news about Fidelity National Information Services.
5. Castle Biosciences (CSTL) – Premarket: 3.13%
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
NASDAQ ended the session with Castle Biosciences sliding 1.24% to $13.55 on Wednesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.65.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.33%.
Yearly Top and Bottom Value
Castle Biosciences’s stock is valued at $13.55 at 08:34 EST, way under its 52-week high of $36.10 and way above its 52-week low of $9.26.
More news about Castle Biosciences.
6. Fastenal Company (FAST) – Premarket: 3.01%
Fastenal Company, together with its subsidiaries, engages in the wholesale distribution of industrial and construction supplies in the United States, Canada, Mexico, and internationally. It offers fasteners, and related industrial and construction supplies under the Fastenal name. The company's fastener products include threaded fasteners, bolts, nuts, screws, studs, and related washers, which are used in manufactured products and construction projects, as well as in the maintenance and repair of machines. It also offers miscellaneous supplies and hardware, including pins, machinery keys, concrete anchors, metal framing systems, wire ropes, strut products, rivets, and related accessories. The company serves the manufacturing market comprising original equipment manufacturers; maintenance, repair, and operations customers; and non-residential construction market, which includes general, electrical, plumbing, sheet metal, and road contractors. It also serves farmers, truckers, railroads, mining companies, schools, and retail trades; and oil exploration, production, and refinement companies, as well as federal, state, and local governmental entities. Fastenal Company was founded in 1967 and is headquartered in Winona, Minnesota.
NASDAQ ended the session with Fastenal Company falling 0.98% to $58.41 on Wednesday while NASDAQ jumped 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Fastenal Company has a trailing twelve months EPS of $1.95.
PE Ratio
Fastenal Company has a trailing twelve months price to earnings ratio of 29.95. Meaning, the purchaser of the share is investing $29.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.69%.
Yearly Top and Bottom Value
Fastenal Company’s stock is valued at $58.41 at 08:34 EST, below its 52-week high of $59.30 and way above its 52-week low of $43.73.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 4% and 2%, respectively.
More news about Fastenal Company.
7. Sumitomo Mitsui (SMFG) – Premarket: 3.01%
Sumitomo Mitsui Financial Group, Inc., together with its subsidiaries, provides banking, leasing, securities, credit card, and consumer finance services. It operates through four segments: Wholesale Business Unit, Retail Business Unit, Global Business Unit, and Global Markets Business Unit. Sumitomo Mitsui Financial Group, Inc. was incorporated in 2002 and is headquartered in Tokyo, Japan.
NYSE ended the session with Sumitomo Mitsui rising 0.47% to $8.64 on Wednesday while NYSE jumped 0.27% to $15,918.50.
Earnings Per Share
As for profitability, Sumitomo Mitsui has a trailing twelve months EPS of $0.82.
PE Ratio
Sumitomo Mitsui has a trailing twelve months price to earnings ratio of 10.54. Meaning, the purchaser of the share is investing $10.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.38%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Sep 28, 2022, the estimated forward annual dividend rate is 0.32 and the estimated forward annual dividend yield is 3.89%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 960.8%, now sitting on 3.99T for the twelve trailing months.
Volatility
Sumitomo Mitsui’s last week, last month’s, and last quarter’s current intraday variation average was 0.74%, 0.30%, and 1.25%.
Sumitomo Mitsui’s highest amplitude of average volatility was 0.92% (last week), 1.21% (last month), and 1.25% (last quarter).
Moving Average
Sumitomo Mitsui’s worth is above its 50-day moving average of $8.19 and way higher than its 200-day moving average of $7.36.
More news about Sumitomo Mitsui.
8. Genuine Parts Company (GPC) – Premarket: 3%
Genuine Parts Company distributes automotive replacement parts, and industrial parts and materials. It operates through Automotive Parts Group and Industrial Parts Group segments. The company distributes automotive replacement parts for hybrid and electric vehicles, trucks, SUVs, buses, motorcycles, recreational vehicles, farm vehicles, small engines, farm equipment, marine equipment, and heavy duty equipment; and accessory and supply items used by various automotive aftermarket customers, such as repair shops, service stations, fleet operators, automobile and truck dealers, leasing companies, bus and truck lines, mass merchandisers, farms, and individuals. It also distributes industrial replacement parts and related supplies, such as bearings, mechanical and electrical power transmission products, industrial automation and robotics, hoses, hydraulic and pneumatic components, industrial and safety supplies, and material handling products for original equipment manufacturer, as well as maintenance, repair, and operation customers in equipment and machinery, food and beverage, forest product, primary metal, pulp and paper, mining, automotive, oil and gas, petrochemical, pharmaceutical, power generation, alternative energy, government, transportation, ports, and other industries. In addition, the company provides various services and repairs comprising gearbox and fluid power and process pump assembly and repair, hydraulic drive shaft repair, electrical panel assembly and repair, hose and gasket manufacture and assembly. It operates in the United States, Canada, France, the United Kingdom, Ireland, Germany, Poland, the Netherlands, Belgium, Spain, Portugal, Australia, New Zealand, Mexico, Indonesia, and Singapore. Genuine Parts Company was incorporated in 1928 and is headquartered in Atlanta, Georgia.
NYSE ended the session with Genuine Parts Company sliding 0.73% to $167.99 on Wednesday while NYSE rose 0.27% to $15,918.50.
Earnings Per Share
As for profitability, Genuine Parts Company has a trailing twelve months EPS of $8.73.
PE Ratio
Genuine Parts Company has a trailing twelve months price to earnings ratio of 19.24. Meaning, the purchaser of the share is investing $19.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.88%.
Volume
Today’s last reported volume for Genuine Parts Company is 631504 which is 29.68% below its average volume of 898101.
Volatility
Genuine Parts Company’s last week, last month’s, and last quarter’s current intraday variation average was 0.58%, 0.53%, and 0.97%.
Genuine Parts Company’s highest amplitude of average volatility was 1.07% (last week), 0.89% (last month), and 0.97% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 6.4% and 6.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.9%, now sitting on 22.57B for the twelve trailing months.
More news about Genuine Parts Company.
9. Astrazeneca (AZN) – Premarket: 2.8%
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
NYSE ended the session with Astrazeneca dropping 8.83% to $65.25 on Wednesday, following the last session’s downward trend. NYSE jumped 0.27% to $15,918.50, after three sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Astrazeneca has a trailing twelve months EPS of $1.53.
PE Ratio
Astrazeneca has a trailing twelve months price to earnings ratio of 42.65. Meaning, the purchaser of the share is investing $42.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.05%.
Moving Average
Astrazeneca’s value is way below its 50-day moving average of $73.73 and below its 200-day moving average of $67.05.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Astrazeneca’s stock is considered to be overbought (>=80).
More news about Astrazeneca.
10. Ebix (EBIX) – Premarket: 2.78%
Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.
NASDAQ ended the session with Ebix rising 4.21% to $26.26 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.21% to $13,816.77, after two sequential sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Ebix has a trailing twelve months EPS of $1.53.
PE Ratio
Ebix has a trailing twelve months price to earnings ratio of 17.16. Meaning, the purchaser of the share is investing $17.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.31%.
Volume
Today’s last reported volume for Ebix is 309444 which is 42.1% below its average volume of 534467.
More news about Ebix.
Premarket Losers Today
1. West Pharmaceutical (WST) – Premarket: -9.34%
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
NYSE ended the session with West Pharmaceutical dropping 1.08% to $378.33 on Wednesday, after two sequential sessions in a row of losses. NYSE jumped 0.27% to $15,918.50, after three sequential sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, West Pharmaceutical has a trailing twelve months EPS of $7.28.
PE Ratio
West Pharmaceutical has a trailing twelve months price to earnings ratio of 51.97. Meaning, the purchaser of the share is investing $51.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.64%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, West Pharmaceutical’s stock is considered to be overbought (>=80).
Sales Growth
West Pharmaceutical’s sales growth is negative 0.9% for the ongoing quarter and 0.9% for the next.
More news about West Pharmaceutical.
2. Canopy Growth (CGC) – Premarket: -4.41%
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
NASDAQ ended the session with Canopy Growth rising 52.1% to $0.59 on Wednesday while NASDAQ jumped 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Canopy Growth has a trailing twelve months EPS of $-4.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.11%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 27.6%, now sitting on 402.9M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Canopy Growth’s EBITDA is -7.28.
Yearly Top and Bottom Value
Canopy Growth’s stock is valued at $0.59 at 08:34 EST, way below its 52-week high of $4.77 and way above its 52-week low of $0.38.
Previous days news about Canopy Growth
- Canopy growth (cgc) improves liquidity with another selloff. According to Zacks on Monday, 3 July, "As a result, Canopy Growth is now better positioned to achieve its goal of becoming an asset-light, North America-focused cannabis business.", "As the cannabis industry continues to evolve, Canopy Growth remains committed to delivering innovative products that enhance the lives of consumers while creating sustainable value for shareholders."
More news about Canopy Growth.
3. Upland Software (UPLD) – Premarket: -4.02%
Upland Software, Inc. provides cloud-based enterprise work management software in the United States, the United Kingdom, Canada, and internationally. It offers a family of software applications under the Upland brand in the areas of marketing, sales, contact center, project management, information technology, business operations, and human resources and legal. The company also provides professional services, such as implementation, data extraction, integration and configuration, and training services, as well as customer support services. It serves large global corporations, various government agencies, and small and medium-sized businesses, as well as financial, consulting, technology, manufacturing, media, telecommunication, political, healthcare, life sciences, and retail and hospitality sectors. The company was formerly known as Silverback Enterprise Group, Inc. and changed its name to Upland Software, Inc. in November 2013. Upland Software, Inc. was incorporated in 2010 and is headquartered in Austin, Texas.
NASDAQ ended the session with Upland Software rising 3.33% to $3.72 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.21% to $13,816.77, after two consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Upland Software has a trailing twelve months EPS of $-6.45.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.96%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 2.1%, now sitting on 315.64M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 58.2% and a negative 52%, respectively.
Moving Average
Upland Software’s worth is way above its 50-day moving average of $3.36 and way below its 200-day moving average of $6.29.
Sales Growth
Upland Software’s sales growth is negative 8.6% for the present quarter and negative 5.2% for the next.
More news about Upland Software.
4. Riot Blockchain (RIOT) – Premarket: -3.81%
Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.
NASDAQ ended the session with Riot Blockchain jumping 12.94% to $13.35 on Wednesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Riot Blockchain has a trailing twelve months EPS of $-4.29.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.54%.
More news about Riot Blockchain.
5. DISH Network (DISH) – Premarket: -3.69%
DISH Network Corporation, together with its subsidiaries, provides pay-TV services in the United States. The company operates in two segments, Pay-TV and Wireless. It offers video services under the DISH TV brand; and programming packages that include programming through national broadcast networks, local broadcast networks, and national and regional cable networks, as well as regional and specialty sports channels, premium movie channels, and Latino and international programming packages. The company also provides access to movies and television shows through TV or Internet-connected devices; and dishanywhere.com and mobile applications on Internet-connected devices to view authorized content, search program listings, and remotely control certain features of their DVRs. In addition, it offers Sling TV services, including Sling domestic, Sling International, Sling Latino, Sling Orange, and Sling Blue services that require an internet connection and are available on streaming-capable devices, such as streaming media devices, TVs, tablets, computers, game consoles, and phones, as well as market SLING TV services to consumers who do not subscribe to traditional satellite and cable pay-TV services. Further, the company provides wireless subscribers consumer plans with no annual service contracts, as well as monthly service plans, including high-speed data and unlimited talk and text. The company offers receiver systems and programming through direct sales channels, as well as independent third parties, such as small retailers, direct marketing groups, local and regional consumer electronics stores, retailers, and telecommunications companies. DISH Network Corporation was founded in 1980 and is headquartered in Englewood, Colorado.
NASDAQ ended the session with DISH Network jumping 2.73% to $6.77 on Wednesday while NASDAQ jumped 0.21% to $13,816.77.
Earnings Per Share
As for profitability, DISH Network has a trailing twelve months EPS of $3.47.
PE Ratio
DISH Network has a trailing twelve months price to earnings ratio of 1.95. Meaning, the purchaser of the share is investing $1.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.36%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.6%, now sitting on 16.31B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DISH Network’s stock is considered to be oversold (<=20).
More news about DISH Network.
6. Marathon (MARA) – Premarket: -3.59%
Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.
NASDAQ ended the session with Marathon jumping 10.53% to $15.32 on Wednesday, after three consecutive sessions in a row of gains. NASDAQ jumped 0.21% to $13,816.77, after two consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Marathon has a trailing twelve months EPS of $-6.3.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.2%.
Volatility
Marathon’s last week, last month’s, and last quarter’s current intraday variation average was 5.28%, 2.86%, and 5.77%.
Marathon’s highest amplitude of average volatility was 5.28% (last week), 5.42% (last month), and 5.77% (last quarter).
More news about Marathon.
7. Banco Santander (SAN) – Premarket: -3.47%
Banco Santander, S.A. provides various retail and commercial banking products and services to individuals, small and medium-sized enterprises, and large companies worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, and current and savings accounts; mortgages, consumer finance, syndicated corporate loans, cash management, export and agency finance, trade and working capital solutions, and corporate finance; and insurance products. The company also provides cash, asset, and wealth management; and private banking services. In addition, it is involved in the corporate banking, treasury, risk hedging, foreign trade, and investment banking activities, as well as provides digital payment solutions. The company was formerly known as Banco Santander Central Hispano S.A. and changed its name to Banco Santander, S.A. in June 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.
NYSE ended the session with Banco Santander jumping 1.08% to $3.75 on Wednesday while NYSE jumped 0.27% to $15,918.50.
Earnings Per Share
As for profitability, Banco Santander has a trailing twelve months EPS of $0.6.
PE Ratio
Banco Santander has a trailing twelve months price to earnings ratio of 6.25. Meaning, the purchaser of the share is investing $6.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.82%.
More news about Banco Santander.
8. Aurora Cannabis (ACB) – Premarket: -3.46%
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Leduc, Canada.
NYSE ended the session with Aurora Cannabis rising 8.51% to $0.58 on Wednesday, after two consecutive sessions in a row of gains. NYSE jumped 0.27% to $15,918.50, after three sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-5.91.
Volatility
Aurora Cannabis’s last week, last month’s, and last quarter’s current intraday variation average was 3.25%, 0.64%, and 3.07%.
Aurora Cannabis’s highest amplitude of average volatility was 3.43% (last week), 3.79% (last month), and 3.07% (last quarter).
Volume
Today’s last reported volume for Aurora Cannabis is 4552150 which is 42.35% above its average volume of 3197830.
More news about Aurora Cannabis.
9. Prudential Public Limited Company (PUK) – Premarket: -3.22%
Prudential plc, through its subsidiaries, provides life and health insurance, and retirement and asset management solutions to individuals in Asia, and Africa. It offers health and protection, as well as non- participating savings products, such as protection and investment-linked products. The company also provides insurance against common critical illnesses; property and casualty; and tropical disease protection, such as dengue, malaria, and measles. The company was founded in 1848 and is headquartered in London, the United Kingdom.
NYSE ended the session with Prudential Public Limited Company sliding 0.11% to $28.29 on Wednesday while NYSE jumped 0.27% to $15,918.50.
Earnings Per Share
As for profitability, Prudential Public Limited Company has a trailing twelve months EPS of $0.73.
PE Ratio
Prudential Public Limited Company has a trailing twelve months price to earnings ratio of 38.75. Meaning, the purchaser of the share is investing $38.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.86%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 22, 2023, the estimated forward annual dividend rate is 0.38 and the estimated forward annual dividend yield is 1.37%.
Volume
Today’s last reported volume for Prudential Public Limited Company is 229003 which is 46.97% below its average volume of 431840.
Yearly Top and Bottom Value
Prudential Public Limited Company’s stock is valued at $28.29 at 08:34 EST, way below its 52-week high of $34.37 and way above its 52-week low of $18.20.
More news about Prudential Public Limited Company.
10. Wipro Limited (WIT) – Premarket: -3.13%
Wipro Limited operates as an information technology (IT), consulting, and business process services company worldwide. It operates through three segments: IT Services, IT Products, and India State Run Enterprise Services (ISRE). The IT Services segment offers IT and IT-enabled services, including digital strategy advisory, customer-centric design, technology and IT consulting, custom application design, development, re-engineering and maintenance, systems integration, package implementation, cloud and infrastructure, business process, cloud, mobility and analytics, research and development, and hardware and software design services to enterprises. It serves customers in various industry sectors, such as healthcare and medical devices, consumer goods and life sciences, retail, transportation and services, communications, media and information services, technology products and platforms, banking, financial services and insurance, manufacturing, hi-tech, energy, and utilities. The IT Products segment provides a range of third-party IT products comprising enterprise platforms, networking solutions, software and data storage products, contact center infrastructure, enterprise security, IT optimization technologies, video solutions, and end-user computing solutions. It serves enterprises in various industries primarily in the Indian market, which comprise the government, defense, IT and IT-enabled services, telecommunications, manufacturing, utilities, education, and financial services sectors. The ISRE segment offers IT services to entities and departments owned or controlled by the Government of India and/or various Indian State Governments. It also provides cybersecurity consulting services. The company was incorporated in 1945 and is based in Bengaluru, India.
NYSE ended the session with Wipro Limited rising 1.38% to $4.79 on Wednesday while NYSE rose 0.27% to $15,918.50.
Earnings Per Share
As for profitability, Wipro Limited has a trailing twelve months EPS of $0.25.
PE Ratio
Wipro Limited has a trailing twelve months price to earnings ratio of 19.14. Meaning, the purchaser of the share is investing $19.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.78%.
More news about Wipro Limited.
Stay up to date with our premarket winners and losers daily report
